Log in

NYSE:CRLCharles River Laboratories Intl. Stock Price, Forecast & News

$198.99
-2.32 (-1.15 %)
(As of 07/31/2020 04:00 PM ET)
Add
Compare
Today's Range
$195.48
Now: $198.99
$202.24
50-Day Range
$169.00
MA: $183.54
$201.31
52-Week Range
$95.58
Now: $198.99
$203.26
Volume285,977 shs
Average Volume330,965 shs
Market Capitalization$9.85 billion
P/E Ratio40.04
Dividend YieldN/A
Beta1.22
Charles River Laboratories International, Inc., an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates in three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment produces and sells research model strains primarily purpose-bred rats and mice for use by researchers. It also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification of a druggable target through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as bioanalysis, drug metabolism, pharmacokinetics, safety pharmacology, toxicology, and pathology services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile biopharmaceuticals, and consumer products. It also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company serves biopharmaceutical companies; biotechnology, agricultural and industrial chemical, life science, veterinary medicine, medical device, diagnostic, and consumer product companies; contract research and contract manufacturing organizations; other commercial entities; and hospitals, academic institutions, and government agencies. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.
Read More
Charles River Laboratories Intl. logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.4Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.40 out of 5 stars


Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryLife Sciences Tools & Services
SectorMedical
CUSIP15986410
Phone781-222-6000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.62 billion
Cash Flow$10.87 per share
Book Value$33.45 per share

Profitability

Net Income$252.02 million

Miscellaneous

Employees17,100
Market Cap$9.85 billion
Next Earnings Date8/5/2020 (Confirmed)
OptionableOptionable
$198.99
-2.32 (-1.15 %)
(As of 07/31/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CRL News and Ratings via Email

Sign-up to receive the latest news and ratings for CRL and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Charles River Laboratories Intl. (NYSE:CRL) Frequently Asked Questions

How has Charles River Laboratories Intl.'s stock been impacted by COVID-19 (Coronavirus)?

Charles River Laboratories Intl.'s stock was trading at $136.60 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, CRL stock has increased by 45.7% and is now trading at $198.99.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Charles River Laboratories Intl.?

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Charles River Laboratories Intl. in the last year. There are currently 3 hold ratings, 14 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Charles River Laboratories Intl.
.

When is Charles River Laboratories Intl.'s next earnings date?

Charles River Laboratories Intl. is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020.
View our earnings forecast for Charles River Laboratories Intl.
.

How can I listen to Charles River Laboratories Intl.'s earnings call?

Charles River Laboratories Intl. will be holding an earnings conference call on Wednesday, August 5th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Charles River Laboratories Intl.'s earnings last quarter?

Charles River Laboratories Intl. Inc (NYSE:CRL) released its quarterly earnings data on Thursday, May, 7th. The medical research company reported $1.84 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $1.46 by $0.38. The medical research company earned $707.06 million during the quarter, compared to the consensus estimate of $692.11 million. Charles River Laboratories Intl. had a return on equity of 22.69% and a net margin of 9.09%. The firm's revenue was up 17.0% compared to the same quarter last year. During the same period in the prior year, the business earned $1.40 earnings per share.
View Charles River Laboratories Intl.'s earnings history
.

What guidance has Charles River Laboratories Intl. issued on next quarter's earnings?

Charles River Laboratories Intl. updated its FY20 earnings guidance on Thursday, May, 7th. The company provided earnings per share (EPS) guidance of $6.75-7.10 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $6.41. The company issued revenue guidance of $2.74-2.83 billion, compared to the consensus revenue estimate of $2.75 billion.

What price target have analysts set for CRL?

18 Wall Street analysts have issued 1 year target prices for Charles River Laboratories Intl.'s stock. Their forecasts range from $139.00 to $236.00. On average, they expect Charles River Laboratories Intl.'s share price to reach $178.83 in the next year. This suggests that the stock has a possible downside of 10.1%.
View analysts' price targets for Charles River Laboratories Intl.
.

Has Charles River Laboratories Intl. been receiving favorable news coverage?

News stories about CRL stock have been trending negative recently, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Charles River Laboratories Intl. earned a media sentiment score of -2.9 on InfoTrie's scale. They also assigned media headlines about the medical research company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the immediate future.
View the latest news about Charles River Laboratories Intl.
.

Are investors shorting Charles River Laboratories Intl.?

Charles River Laboratories Intl. saw a drop in short interest in the month of July. As of July 15th, there was short interest totaling 861,800 shares, a drop of 16.3% from the June 30th total of 1,030,000 shares. Based on an average daily trading volume, of 382,000 shares, the days-to-cover ratio is currently 2.3 days. Approximately 1.8% of the shares of the stock are short sold.
View Charles River Laboratories Intl.'s Current Options Chain
.

Who are some of Charles River Laboratories Intl.'s key competitors?

What other stocks do shareholders of Charles River Laboratories Intl. own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Charles River Laboratories Intl. investors own include Alibaba Group (BABA), NVIDIA (NVDA), salesforce.com (CRM), Adobe (ADBE), Boeing (BA), Pfizer (PFE), Intel (INTC), Intuitive Surgical (ISRG), Vertex Pharmaceuticals (VRTX) and AbbVie (ABBV).

Who are Charles River Laboratories Intl.'s key executives?

Charles River Laboratories Intl.'s management team includes the following people:
  • Mr. James C. Foster, Chairman, CEO & Pres (Age 68)
  • Mr. David Ross Smith, Corp. Exec. VP & CFO (Age 53)
  • Mr. David P. Johst, Corp. Exec. VP, HR, Gen. Counsel & Chief Admin. Officer (Age 57)
  • Mr. William D. Barbo, Chief Commercial Officer & Corp. Exec. VP (Age 58)
  • Mr. Michael Gunnar Knell, Corp. Sr. VP & Chief Accounting Officer (Age 42)

What is Charles River Laboratories Intl.'s stock symbol?

Charles River Laboratories Intl. trades on the New York Stock Exchange (NYSE) under the ticker symbol "CRL."

Who are Charles River Laboratories Intl.'s major shareholders?

Charles River Laboratories Intl.'s stock is owned by many different institutional and retail investors. Top institutional investors include Copper Rock Capital Partners LLC (8.70%), Congress Asset Management Co. MA (1.27%), First Trust Advisors LP (1.18%), Trinity Street Asset Management LLP (0.50%), Confluence Investment Management LLC (0.42%) and Retirement Systems of Alabama (0.27%). Company insiders that own Charles River Laboratories Intl. stock include Birgit Girshick, David P Johst, David Ross Smith, Deborah Turner Kochevar, George M Milne Jr, George Massaro, James C Foster, Joseph W Laplume, Robert J Bertolini, Stephen D Chubb and William D Barbo.
View institutional ownership trends for Charles River Laboratories Intl.
.

Which institutional investors are selling Charles River Laboratories Intl. stock?

CRL stock was sold by a variety of institutional investors in the last quarter, including Boston Trust Walden Corp, Mackay Shields LLC, Monarch Partners Asset Management LLC, Retirement Systems of Alabama, Congress Asset Management Co. MA, Nisa Investment Advisors LLC, SG Americas Securities LLC, and Norris Perne & French LLP MI. Company insiders that have sold Charles River Laboratories Intl. company stock in the last year include Birgit Girshick, David Ross Smith, George Massaro, James C Foster, Robert J Bertolini, and William D Barbo.
View insider buying and selling activity for Charles River Laboratories Intl.
.

Which institutional investors are buying Charles River Laboratories Intl. stock?

CRL stock was purchased by a variety of institutional investors in the last quarter, including Copper Rock Capital Partners LLC, Mountain Pacific Investment Advisers Inc. ID, Confluence Investment Management LLC, Raymond James & Associates, Prudential PLC, First Trust Advisors LP, Trinity Street Asset Management LLP, and Raymond James Financial Services Advisors Inc..
View insider buying and selling activity for Charles River Laboratories Intl.
.

How do I buy shares of Charles River Laboratories Intl.?

Shares of CRL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Charles River Laboratories Intl.'s stock price today?

One share of CRL stock can currently be purchased for approximately $198.99.

How big of a company is Charles River Laboratories Intl.?

Charles River Laboratories Intl. has a market capitalization of $9.85 billion and generates $2.62 billion in revenue each year. The medical research company earns $252.02 million in net income (profit) each year or $6.73 on an earnings per share basis. Charles River Laboratories Intl. employs 17,100 workers across the globe.

What is Charles River Laboratories Intl.'s official website?

The official website for Charles River Laboratories Intl. is www.criver.com.

How can I contact Charles River Laboratories Intl.?

Charles River Laboratories Intl.'s mailing address is 251 BALLARDVALE STREET, WILMINGTON MA, 01887. The medical research company can be reached via phone at 781-222-6000 or via email at [email protected]

This page was last updated on 8/3/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.